Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath–Tacrolimus vs IL2R MoAb–Tacrolimus/Mycophenolate as induction–maintenance in kidney transplantation
2005-002856-17Phase 4Completed
- Sponsor
- Hammersmith Hospitals NHS Trust
- Start
- Oct 2006
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in kidney allograft rejection and Kidney allograft failure comparing Campath + tacrolimus with Zenapax + tacrolimus + Cellcept (2 arms). Primary endpoint: One-year patient survival with functioning kidney transplant. Started Oct 2006; status: completed.
02
Drugs
alemtuzumabtacrolimusdaclizumabmycophenolate mofetil
03
Conditions
kidney allograft rejectionKidney allograft failure
Beyond the preview
Go deeper on 2005-002856-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002856-17.